ALT Q4 2019 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$575,801-77.8% YoY

Gross Profit

-$2M-277.4% margin

Operating Income

-$4M-748.9% margin

Net Income

-$4M-711.5% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-10.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$278,971

Balance Sheet

Total Assets

$54M

Total Liabilities

$9M

Stockholders' Equity

$46M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$575,801	$3M	-77.8%
Gross Profit	-$2M	-$476,040	-235.5%
Operating Income	-$4M	-$27M	+84.2%
Net Income	-$4M	-$25M	+83.3%